NCT02231762 - Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

June 30, 2017

Conditions

Gastroenteropancreatic Neuroendocrine Tumors

Interventions

DRUG

Lanreotide Autogel 120 mg

Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).

DRUG

Temozolomide (TMZ)

Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.

Trial Locations (10)

Vienna General Hospital, Vienna

Charité University Hospital, Berlin

ENDOC Hamburg, Hamburg

Oncological Center Leer, Leer

University Hospital Marburg, Marburg

University Hospital Essen, Essen

University Hospital Mainz, Mainz

University Hospital Mannheim, Mannheim

University Hospital Munich, Munich

Zentralklinik Bad Berka, Bad Berka